Bariatric or metabolic surgery can significantly lower the risk of major cardiovascular events among patients with Type 2 diabetes and obesity, according to a new clinical study released at the European Society of Cardiology Congress in Paris. The retrospective study followed 13,722 Type 2 diabetes patients who underwent bariatric surgery to lose weight or metabolic […]
Ablative Solutions taps medtech vet Rumrill for CEO | Personnel Moves, July 16, 2019
Ablative Solutions tapped 30-year industry veteran Kate Rumrill, the former chief executive at NeoSync, to be its new president & CEO. Rumrill, whose resume includes stints at Covidien, Aspect Medical Systems and Eli Lilly, is slated to keep her seat on NeoSync’s board, San Jose, Calif.-based Ablative Solutions said. The company makes the Peregine renal […]
Ablative Solutions closes $77m Series D
Ablative Solutions said today that it closed a $77 million Series D funding round to help support its technology platform intended to treat hypertension. The round was led by newly invested Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor, the Kalamazoo, Mich.-based company said. Existing investors Michigan […]
Infusion catheter developer Ablative Solutions raises $4m
Delaware-based Ablative Solutions has raised $4 million as part of a $10 million round, according to regulatory filings. The company is developing the Peregrine System, an infusion catheter that delivers diagnostic and therapeutic agents to the perivascular space surrounding blood vessels. The 510(k)-cleared device includes three microneedles that remain within radiopaque guide tubes prior to drug delivery. After […]
Ablative Solutions wins FDA nod for Phase II chemical denervation trial
Ablative Solutions said today that the FDA approved a Phase II trial of its chemical denervation system for hypertension under its investigational new drug application. The trial, called Target-BP I, will evaluate the efficacy of Ablative’s Peregrine infusion ablation system, which uses ethanol to interrupt signals from sympathetic nerves in the renal artery to control […]
Ablative Solutions raises $2.4m, looks for $4m more
Ablative Solutions has pulled in $2.4 million in a new round of financing, looking to raise another $4 million in the round, according to an SEC filing posted last week. The Kalamazoo, Mich.-based company developed and produces the Peregrine infusion ablation catheter for treating hypertension. The Peregrine system infuses neurolytic agents into the perivascular space […]
Renal denervation: Ablative Solutions wins CE Mark for chemical ablation catheter
Ablative Solutions said it received CE Mark approval for its Peregrine infusion ablation catheter for treating uncontrolled hypertension. The company began testing Peregrine last year in Poland.
Ablative Solutions tests infusion ablation catheter as hypertension treatment
Hypertension: Ablative Solutions lands $8M for renal denervation tech
Ablative Solutions, which is developing perivascular renal denervation technology for treating high blood pressure, raised an $8.0 million funding round, according to a regulatory filing.
Menlo Park, Calif.-based Ablative Solutions said 98 unnamed investors participated in the funding round, which consisted of debt, options and warrants.
Hypertension: Ablative Solutions reels in $2.7M for renal denervation device
Ablative Solutions added to its coffers yesterday, reporting a $2.7 million raise out of a hoped-for $5 million as it works to develop its perivascular renal denervation technology for treating high blood pressure.
Menlo Park, Calif.-based Ablative said 41 unnamed investors joined the debt, options and warrants round.
Medtech funding: Ablative Solutions raises $1.1 million
Ablative Solutions reported raising $1.1 million in an April 4, 2013, regulatory filing:
Company: Ablative Solutions
Raise: $1.1 million
Security: Debt, Options/Warrants
Investors: 13
Sales Commission: $0
Finders’ Fees: $0
MassDevice Network
@MassDevice
LinkedIn
YouTube